Lindus Health has announced a collaboration with the Clinical Data Interchange Standards Consortium (CDISC) to accelerate the development of standardized Biomedical Concepts using AI-driven technology. The initiative aims to streamline clinical trial data collection, sharing, and analysis, improving efficiency across the industry.
AI-driven efficiency in clinical trial data standardization
CDISC develops global data standards required by regulatory agencies, including the U.S. Food and Drug Administration (FDA), to ensure structured and interpretable clinical trial data. The process of creating Biomedical Concepts, which link clinical observations across studies, has traditionally been manual and time-consuming.
By integrating AI models, Lindus Health will:
- Accelerate the generation of Biomedical Concepts, reducing reliance on labor-intensive processes.
- Improve consistency in clinical trial data, facilitating regulatory submissions.
- Enhance interoperability, allowing researchers to share and analyze data more effectively.
CDISC’s large language models (LLMs) will support this initiative by automating terminology standardization, ensuring that data remains harmonized across different therapeutic areas.
Industry perspectives on AI’s role in clinical research
“Our partnership with CDISC showcases our commitment to eliminating manual, slow processes in clinical research,” said Meri Beckwith, co-founder of Lindus Health. “We’re excited to leverage AI to improve data standards for the entire industry.”
Peter Van Reusel, chief standards officer at CDISC, emphasized AI’s potential to modernize research and development. “As we expand our Biomedical Concepts library, this collaboration will ensure data quality at scale and drive long-term efficiency in clinical trials.”
Lindus Health’s role in advancing clinical trials
Lindus Health has been at the forefront of AI-driven clinical trial management, optimizing study design, protocol development, and central monitoring. The company has conducted trials across the US, UK, and Europe, covering conditions such as diabetes, asthma, major depressive disorder, and hypertension.
With over $80 million in funding from investors including Peter Thiel, Balderton, and Seedcamp, Lindus Health is working to reduce bottlenecks in clinical research and accelerate the delivery of new treatments to patients.
Featured image credit: Steve Johnson/Unsplash
